2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study

BACKGROUND: Mold-active antifungal prophylaxis (ppx) is recommended in neutropenic patients with newly diagnosed AML or MDS. ISAV is an extended spectrum triazole with superior tolerability, reliability of absorption, fewer drug–drug interactions, lack of QT(c) prolongation or need for therapeutic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Kadia, Tapan M, Borthakur, Gautam, Ravandi-Kashani, Farhad, Masarova, Lucia, Konopleva, Marina, Estrov, Zeev, Takahashi, Koichi, Yilmaz, Musa, Rausch, Caitlin R, Marx, Kayleigh, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811325/
http://dx.doi.org/10.1093/ofid/ofz360.1801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811325/
http://dx.doi.org/10.1093/ofid/ofz360.1801

Ejemplares similares